Clinical trials of endothelin antagonists in heart failure: a question of dose?

Area of Science:

• Cardiology
• Pharmacology
• Biomedical Research

Background:

• Elevated circulating endothelin (ET)-1 is observed in chronic heart failure (CHF) and correlates with disease severity.
• Preclinical studies showed ET antagonists improved hemodynamics and survival in experimental heart failure models.
• ET receptor antagonists demonstrated positive effects on systemic and pulmonary hemodynamics in CHF patients without neurohormonal activation.

Purpose of the Study:

• To analyze the reasons behind the neutral effects of ET antagonists in recent CHF clinical trials.
• To derive lessons from the ENABLE and EARTH studies for the design of future clinical investigations.

Main Methods:

• Review of clinical trial data from ENABLE and EARTH studies.
• Analysis of potential factors contributing to the lack of observed benefit.
• Discussion of study design elements and patient populations.

Main Results:

• Recent large-scale clinical trials (ENABLE, EARTH) reported neutral effects of ET antagonists on mortality and symptoms in CHF patients.
• Despite promising preclinical and early clinical hemodynamic data, significant clinical benefit was not achieved.

Conclusions:

• The discrepancy between preclinical/hemodynamic findings and clinical outcomes warrants further investigation.
• Lessons learned from past studies are crucial for optimizing the design and execution of future therapeutic strategies targeting the endothelin system in heart failure.